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OpReply to: ‘‘Non-invasive diagnosis of small nodules in cirrhosis’’To the Editor:
We appreciate Dr. Fujita comments on our study on the diag-
nostic accuracy of contrast enhanced CT-scan to evaluate the
dynamic vascular enhancement pattern of intrahepatic cholan-
giocarcinoma (ICC) in cirrhotic patients [1]. One comment is
that lack of the radiological hallmark of hepatocellular carci-
noma (HCC, wash-in followed by wash-out) does not preclude
the diagnosis of an HCC with an atypical vascular behavior
and that the typical hallmark is less often found in small and
well differentiated tumors. We could not agree more on this
remark, which is in agreement, and not in contrast, with our
article. Indeed, we also previously reported that the radiological
contrast imaging hallmark of HCC occurs in less than 25% of
small well differentiated HCCs [2]. To limit the rates of false
negative diagnosis and thus the need for biopsies, we therefore
suggested the sequential application of contrast imaging tech-
niques, i.e., contrast enhanced CT-scan (CT), magnetic resonance
(MRI) or ultrasound (CEUS), accompanied by histological charac-
terization of the nodule whenever radiology fails to provide a
diagnosis [3]. As a matter of fact, this algorithm with CT and
MRI as imaging techniques has been endorsed by the American
Association for the Study of Liver Disease [4] and partially by
the European Association for the Study of the Liver [5]. With
the addition of CEUS, the algorithm has been adopted in Italy
[6] and in Asia [7,8]. Additionally, Dr. Fujita points out that
the similar behavior of ICC smaller or larger than 3 cm is some-
how unexpected. What is important to note is that most of our
ICC were discovered during surveillance of cirrhotic patients,
which means that even those beyond 3 cm (a minority of cases,
less than 40%) were actually only rarely large (>5 cm), which
could explain the possible discrepancy with previous reports
in which tumors >3 cm were most often very large, implying a
higher rate of intratumoral necrosis leading to atypical patterns.
Moreover, we disagree on Dr. Fujita comments on the interpre-
tation of the discrepancies in the diagnostic accuracy of contrast
CT scan between ours and the study by Kim et al. concerning
nodules less than 3 cm in size [9]. We would like to think that
such discrepancies reﬂect a misinterpretation of the study
results, possibly owing to the adoption of different CT-scan
techniques and application of different protocols of image
acquisition, speciﬁcally, the lack of a delayed venous phase anal-
ysis in Kim study, i.e., the absence of an overview of all phases
of CT-scan. Another problem with that study could relate to the
small sample size of the study which included 8 ICCs smaller
than 3 cm only, of which only 2 had central and peripheral
enhancement pattern in the arterial phase, still in the absence
of any detail regarding the corresponding venous pattern. Fur-
ther complicating the interpretation of Kim and colleagues data,Journal of Hepatology 20
en access under CC BY-NC-ND license.are the 5 nodules with a wash-out in the venous phase lacking
any description of the arterial phase. Thus, we strongly believe
that without an accurate description of the enhancement
pattern of the nodules throughout the three vascular phases of
contrast imaging, as we did in our study, it is rather impossible
to establish a diagnosis of HCC ruling out ICC in cirrhosis [1]. In
other words, our conclusion was that CT-scan poorly suffers
from the risk of misdiagnosis of ICC for HCC, but also that ICC
cannot be diagnosed by imaging and requires a biopsy. There-
fore, we are in keeping with the comment of Dr. Fujita that
HCC and ICC with atypical imaging features are likely difﬁcult
to be distinguished from other non-malignant lesions by the
dynamic vascular enhancement pattern on CT-scan alone, which
means that a biopsy is required. On practical ground, we also
previously commented on the role of CEUS in this setting, which
leads to the possibility of using ultrasonography to the same
end [10], with the well-known limits of CEUS in terms of
staging. In this connection, let us also elaborate on Dr. Fujita
comment regarding the diagnostic role of Kupffer cell-
speciﬁc contrast agent Sonazoid in CEUS, which may be used
for the non-invasive diagnosis of small nodules in cirrhosis.
While it is well recognized that the diagnostic ability of this
contrast medium relies on the lack of Kupffer cells in the mes-
enchymal meshwork of the malignant lesions, at variance with
normal and cirrhotic liver parenchyma and most solid benign
liver nodule, thereby resulting in a ﬁlling defect of the contrast
during the post-vascular phase, yet, this CEUS fails to distin-
guish between the two different malignant tumors ICC and
HCC [11].
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The emerging role
To the Editor:
We read with interest the review by Peveling-Oberhag et al. [1]
that provides a very exhaustive picture of the knowledge about
HCV-related B-cell non-Hodgkin lymphomas (NHL), from its con-
nection with the mixed cryoglobulinemia (MC) condition and
epidemiology to pathomechanisms, passing through therapeutic
options.
In spite of the multiple pathogenetic hypotheses proposed for
HCV-related NHL [2], since the link between malignancy and
infection was shown [3–5], the authors clearly explained the
research advances, summarizing them in three different theories:
the sustained B cell stimulation, the direct oncogenic potential of
viral proteins, and the genetic virus-induced damage by a so
called ‘‘hit and run’’ action. Interestingly, the authors include
microRNA dysregulation in the dissertation about the ﬁrst theory,
suggesting a key role of miR-26b downregulation in undermining
tumor suppression [6]. We could recently conﬁrm these data on
NHLs and also, consistently increase the potential importance
of miR-26b levels in determining HCV-related lymphoprolifera-
tion [7]. In fact, our results showed miR-26b downregulation
not only in NHL, but also in MC patients, suggesting its involve-
ment also in this condition, considered to be a prelymphomatous
disorder. More interestingly, in patients who, after antiviral ther-
apy, experienced viral eradication, the MC syndrome disappeared
and miR-26b expression was restored to normal levels. From a
translational point of view, we could show the usefulness of
miR-26b detection in PBMCs, obtainable through non-invasive
blood sampling; this was especially interesting in consideration
of the difﬁculties in detecting miR-26b modiﬁcations in serum
samples of the same MC or NHL patients (personal, unpublished
data), making the PBMC test the easiest way to evaluate this
potential marker through a simple blood drawn. The following,
so far unexplored, step will therefore be the identiﬁcation of
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of miRNA-26b
miR-26b target genes; Peveling and colleagues already suggested
the NEK6 gene coding for a kinase involved in the initiation of
mitosis [6]. In addition, we proposed the lymphoid enhancer fac-
tor 1 (LEF-1) gene [7]. LEF-1 is a nuclear transcription factor tran-
siently expressed in the pro-B and not detectable in mature B
cells, but recently indicated as a speciﬁc target of miR-26b [8];
previous studies showed elevated levels of LEF-1 in human can-
cers, in chronic lymphatic leukemia [9] and in a wide cohort of
diffuse large B cells lymphomas [10], making this a potential tar-
get of special interest in the pathogenetic research ﬁeld.
In conclusion, our results on HCV positive MC strengthen
previous data on the importance of miR-26b modulation in
HCV-related NHL, opening new perspectives for further studies
on target genes and also aimed to a better deﬁnition of this
microRNA as disease biomarker.
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